GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Current Ratio

Petros Pharmaceuticals (Petros Pharmaceuticals) Current Ratio : 1.89 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Petros Pharmaceuticals's current ratio for the quarter that ended in Dec. 2023 was 1.89.

Petros Pharmaceuticals has a current ratio of 1.89. It generally indicates good short-term financial strength.

The historical rank and industry rank for Petros Pharmaceuticals's Current Ratio or its related term are showing as below:

PTPI' s Current Ratio Range Over the Past 10 Years
Min: 0.29   Med: 0.99   Max: 2.08
Current: 1.89

During the past 5 years, Petros Pharmaceuticals's highest Current Ratio was 2.08. The lowest was 0.29. And the median was 0.99.

PTPI's Current Ratio is ranked better than
50.6% of 1077 companies
in the Drug Manufacturers industry
Industry Median: 1.87 vs PTPI: 1.89

Petros Pharmaceuticals Current Ratio Historical Data

The historical data trend for Petros Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals Current Ratio Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
0.29 0.62 0.99 2.08 1.89

Petros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 2.02 1.65 3.02 1.89

Competitive Comparison of Petros Pharmaceuticals's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Petros Pharmaceuticals's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Current Ratio falls into.



Petros Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Petros Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=20.39/10.771
=1.89

Petros Pharmaceuticals's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=20.39/10.771
=1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Petros Pharmaceuticals  (NAS:PTPI) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Petros Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Petros Pharmaceuticals (Petros Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley director 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman director, 10 percent owner
Jcp Iii Sm Aiv, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd. 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan officer: Chief Financial Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor officer: Pres. & Chief Comm. Officer 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek officer: President, Timm Medical 200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc 10 percent owner 5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold officer: Prin. Acct. Off/Prin. Fin. Off 200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726

Petros Pharmaceuticals (Petros Pharmaceuticals) Headlines

From GuruFocus

Petros Pharmaceuticals Announces Reverse Stock Split

By ACCESSWIRE ACCESSWIRE 11-30-2022

Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022

By GlobeNewswire GlobeNewswire 04-28-2022